• Bioluminescence
• Fluorescence
• Cryofluorescence Imaging
• X-ray and Scintigraphy
• Clinical Imaging Systems for Research

• Universal lentiviral vector luciferase reporter backbone for tracking expression of nearly any miRNA
  • Currently available:
    • Lv-miR-control vector (lacks a miRNA target sequence)
    • Lv-Luc-miR-145-5p
    • Lv-Luc-miR-27b-5p
    • Lv-Luc-miR-27b-3p
    • Lv-Luc-miR-21-3p (validation in process)
• Next generation RNA-sequencing (RNA-seq)
• Available Reporter Vectors (validated)
  • Human Aggrecan promoter reporter (Lentiviral vector, dTomato)
  • Human Aggrecan promoter reporter (Lentiviral vector, secreted Gaussia Luciferase)
  • Human COL10A1 promoter reporter (Lentiviral vector, secreted Gaussia Luciferase)
  • Human COL2A1 promoter reporter (Lentiviral vector, secreted Gaussia Luciferase)
  • Human COL2A1 promoter reporter (Plasmid, Firefly Luciferase)
  • Human Osteocalcin promoter reporter (Lentiviral vector, Firefly Luciferase)
  • Human Osteocalcin promoter reporter (Lentiviral vector, dTomato)
  • Human Runx2 promoter reporter (Lentiviral vector, secreted Gaussia Luciferase)
  • Human Sox9 promoter reporter (Lentiviral vector, Firefly Luciferase)
  • Human Sox9 promoter reporter (Lentiviral vector, secreted Gaussia Luciferase)
  • Human Sox9 promoter reporter short sequence (Plasmid, Firefly Luciferase)
  • Human Sox9 promoter reporter full sequence (Plasmid, Firefly Luciferase)
  • Mouse Sox9 promoter reporter full sequence (Plasmid, Firefly Luciferase)
  • Human Sox9 promoter reporter (Lentiviral vector, eGFP)
• Available lentiviral vectors for cell tracking:pLV-Puromicin-dTomato-Luciferase
  • PiggyBack transposon-eGFP-Luciferase
  • pLV-Puromicin-CyPet
  • pLV-Puromicin-YPet
  • pLV-Puromicin-Luciferase
  • pLV-Blasticidin-mCherry-Luciferase
  • pLV-Neomicin-dTomato
  • pLV-Puromicin-eGFP
  • pLV-Secreted Nano-Luciferase
  • pLV-Puromicin-eGFP-Luciferase
• Generation of differentiation markers / promoter-specific viral vectors with traceable gene reporters.
• Efficient viral transduction of primary cells and cell lines.
• Large-scale generation of hybrid structures for in vitro chondrogenesis.
• Bioluminescence Imaging (BLI) of created hybrid structures to assess cell differentiation in real time.
• Structural analysis of engineered tissue sections (Immunohistochemistry) with a panel of Proteoglycan (PG)- and Glycosaminoglycan (GAG)-specific antibodies.
• Immunological assessment of conditioned medium (ELISA) with the same panel of specific antibodies, as an indirect analysis of ECM remodeling.
• Biochemical determination of the GAG composition of generated cartilage ECM.
• MSC-derived human collagen protein
• Cell sorting
• Aptamer development and validation
• TGF-B1 Aptamer-CRISPRCas12 sensor (under validation)
• Non-viral stable integration of reporter genes (tdTomato)
• Confocal microscopy

• Transport modeling and parameter estimation for nutrient consumption in aggregate culture
• Biomolecular rate cut-off determination for success/failure in aggregate culture.
• Donor-specific assessment of metabolism of client-MSC aggregates 
• Donor-specific assessment of metabolism of client-MSC aggregates under varying exogenous factors (to be specified by clients)
• LC/QQQ Amino acid analysis of culture samples
• Amino acid pathway flux balance analysis
• Microbioreactor and splitter for feeding for use in MSC chondrogenesis
  • 16-well conical bottom perfusion microreactor (10 microliter wells)
  • 16-well flat-bottom perfusion microreactor (9 microliter wells)
  • 100-well conical bottom perfusion microreactor (10 microliter wells)
  • 4-way microsplitter
• Quantitative evaluation of metabolism and mass transport in client-TE constructs
• Fluid mixing analysis in bioreactors
• USB-based actuator; hardware and software
• Perfusion bioreactor for culture and mechanical stimulation (flexion) of tissues
• Adhesive oxygen optodes
• Oxygen measurement system
• Oxygen uptake rate sensor.
• Modular bioreactor for tissue culture. The bioreactor is capable of culturing small 1 cm³ to 10 cm³ structural tissues. It has been optimized for mixing and oxygen sensor integration.

• Bioreactor for simultaneous compression/shear stimulation of engineering tissues
• Nonlinear acoustics for estimation of B/A parameter for suspensions and tissue samples.
  • Human MYH3 promoter reporter (Lentiviral vector, Firefly Luciferase)
  • Human TNNT2 promoter reporter (Lentiviral vector, eGFP)
  • Human NFkB reporter (Lentiviral vector, mKate)
  • Human Osteocalcin promoter reporter (Transposon, Firefly Luciferase)
  • CRISPR-dCAS9 vectors (repressors and activators constructs) (validation in process)
• Coefficient of friction measurements for native and engineered cartilage
• High-frequency ultrasound interrogation (50 MHz) of native and engineered tissue to visualize small features
• Surface and internal damage evaluation in tissue engineered and native cartilage using high frequency (30 MHz) ultrasound
• Acoustic anisotropy of cartilage
• Biphasic mechanical properties of native and engineered cartilage using indentation
• Friction and potential damage of native and engineered cartilage under normal load and sliding shear
• Depth dependent shear properties of tissues and tissue engineered constructs
• Quasi-static and dynamic properties of tissues in compression or tension
• Actuator for flexion. A pneumatic actuator can flex tissues in a custom-bioreactor (see below) in a controlled fashion. A USB hardware/software allows for control of parameters (frequency, duration, ) of actuation.
• Actuator for simultaneous compression/shear.
• Bioreactor for flexion. A continuous flow bioreactor that allows for simultaneous flexing of five tissue samples.

• Cloud-based data collection, storage and transformation
• Unsupervised, supervised and deep machine learning
• Exploratory data analysis
• Descriptive and inferential statistics
• Mechanical Testing for tissue and biomaterial characterization
• Additional analytical capabilities
  • Gene expression profiling
  • ELISA and qPCR

• Proteome (LC-MS/MS)
  • Protein identification
  • Untargeted proteomics
  • Molecular weight determination
  • Qualitative protein profiling
  • Identification of post-translational modifications
• Metabolome (LC-MS/MS)
  • Untargeted metabolomics
  • Targeted metabolomics
  • Metabolite assay development
• Lipidome (LC-MS/MS and GC-MS/MS)
  • Untargeted lipidomics
  • Targeted lipidomics

• Development of cell type-specific chemically-defined culture media
• Scalable expansion of autologous and allogeneic pluripotent stem cells, multi-potent stem cells and numerous primary cell types in closed, automated cell culture platforms
• Application of scalable bioprocess equipment for cell and tissue handling
• Closed, automated seeding of synthetic and naturally-derived scaffolds

• General regulatory strategy based upon potential regulatory identity (ies) of the product
  • Development and refinement of specific Target Product Profiles to guide product development toward an IND/IDE for clinical trials for a specific clinical indication.
  • Development of a “regulatory conducive” strategy for product develop for products that may need regulatory approval but may be used in a regulated environment, such as on-line sensors for a regenerative medicine product.
• Preparation of and support for FDA meetings and submissions
  • Preparation of INTERACT, preIND, Qsub, meeting packages and full meeting support.
  • Preparation and electronic submission of 510(k)’s, IND’s, IDE’s, Master Files,
  • Preparation and submission of jurisdictional and special program applications to FDA.

Through its BioFab Startup Lab, ARMI works with startups of all kinds to provide a range of services from strategy, mentorship, physical and technical support from the robust and growing ARMI ecosystem in Manchester and nationwide.